Aridis focuses on anti-infective alternatives to conventional antibiotics


News


>> More News


Mining the human immune response for rare monoclonal antibodies to fight infections

Jun 30th, 2015

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin™ for Treating Hospital-Acquired and Ventilator-Associated Pneumonia (More)

Apr 09th, 2015

Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors.  (More)

Mar 26th, 2015

Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia. (More)

Mar 23rd, 2015

Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical Officer.  (More)